Bulk Inquiry
Tenilsetam
- PAS 997 - CAS 997 - HR 029
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C8H10N2OS
- MW: 182.24
Description
Tenilsetam is a cognition-oriented small molecule and advanced glycation end-product formation inhibitor that interferes with glycation-associated protein cross-linking.
Tenilsetam has been reported to react with glycated proteins and reduce further AGE polymerization, a process relevant to aging, diabetes and neurodegeneration. It is used to study protein glycation, amyloid-associated inflammation and cognitive dysfunction.
Key Features
- Inhibits advanced glycation end-product formation
- Reduces glycation-associated protein cross-linking
- Nootropic pharmacology in preclinical and clinical research
- Relevant to AGE-linked inflammation and neurodegeneration
Applications
- AGE formation and Maillard-reaction assays
- Protein glycation and cross-linking studies
- Diabetic complication models
- Cognition and Alzheimer disease research
More Information
| Parent CAS No. | 86696-86-8 |
|---|---|
| Chemical Name | 3-Thiophen-2-yl-piperazin-2-one |
| SMILES | C1NC(=O)C(C2SC=CC=2)NC1 |
| MFCD | MFCD00867779 |
| InChi | InChI=1S/C8H10N2OS/c11-8-7(9-3-4-10-8)6-2-1-5-12-6/h1-2,5,7,9H,3-4H2,(H,10,11) |
| InChiKey | BBACKDMGYMXYLE-UHFFFAOYSA-N |
| CID | 65649 |
| Short Description | AGE inhibitor |
References
- G Munch et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advance glycosylation. J. Neural. Transm. Sect. 1994, 8(3), 193-208.
- TJ Roesler et al. Advanced glycation end product (AGE) inhibition as a possible pharmacotherapeutic strategy in the treatment of Alzheimer's disease. Drugs Fut. 1999, 24(4), 411.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2303 | R55 |
From $121.00 |
| 2821 | PFM01 |
From $77.00 |
| 2859 | J147 |
From $99.00 |
| 3009 | BRD0539 |
From $187.00 |
| 3027 | FEN1 inhibitor 1 |
From $148.50 |
| 4203 | Pramiracetam |
From $77.00 |
| 4228 | L-742001 hydrochloride |
From $137.50 |
